171 related articles for article (PubMed ID: 19209467)
1. Lipid metabolism in cystic fibrosis.
Worgall TS
Curr Opin Clin Nutr Metab Care; 2009 Mar; 12(2):105-9. PubMed ID: 19209467
[TBL] [Abstract][Full Text] [Related]
2. Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling.
Hamai H; Keyserman F; Quittell LM; Worgall TS
J Lipid Res; 2009 Jun; 50(6):1101-8. PubMed ID: 19144995
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis.
Mingione A; Dei Cas M; Bonezzi F; Caretti A; Piccoli M; Anastasia L; Ghidoni R; Paroni R; Signorelli P
Cell Physiol Biochem; 2020 Jan; 54(1):110-125. PubMed ID: 31999897
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid metabolism in cystic fibrosis.
Strandvik B
Prostaglandins Leukot Essent Fatty Acids; 2010 Sep; 83(3):121-9. PubMed ID: 20673710
[TBL] [Abstract][Full Text] [Related]
5. CFTR regulation of intracellular pH and ceramides is required for lung endothelial cell apoptosis.
Noe J; Petrusca D; Rush N; Deng P; VanDemark M; Berdyshev E; Gu Y; Smith P; Schweitzer K; Pilewsky J; Natarajan V; Xu Z; Obukhov AG; Petrache I
Am J Respir Cell Mol Biol; 2009 Sep; 41(3):314-23. PubMed ID: 19168702
[TBL] [Abstract][Full Text] [Related]
6. CFTR Deletion Confers Mitochondrial Dysfunction and Disrupts Lipid Homeostasis in Intestinal Epithelial Cells.
Kleme ML; Sané A; Garofalo C; Seidman E; Brochiero E; Berthiaume Y; Levy E
Nutrients; 2018 Jun; 10(7):. PubMed ID: 29954133
[TBL] [Abstract][Full Text] [Related]
7. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis.
Teichgräber V; Ulrich M; Endlich N; Riethmüller J; Wilker B; De Oliveira-Munding CC; van Heeckeren AM; Barr ML; von Kürthy G; Schmid KW; Weller M; Tümmler B; Lang F; Grassme H; Döring G; Gulbins E
Nat Med; 2008 Apr; 14(4):382-91. PubMed ID: 18376404
[TBL] [Abstract][Full Text] [Related]
8. CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis.
Westhölter D; Schumacher F; Wülfinghoff N; Sutharsan S; Strassburg S; Kleuser B; Horn PA; Reuter S; Gulbins E; Taube C; Welsner M
J Cyst Fibros; 2022 Jul; 21(4):713-720. PubMed ID: 35168870
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of ceramide in the trachea and intestine of cystic fibrosis mice causes inflammation and cell death.
Becker KA; Tümmler B; Gulbins E; Grassmé H
Biochem Biophys Res Commun; 2010 Dec; 403(3-4):368-74. PubMed ID: 21078296
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory role of extracellular sphingolipids in Cystic Fibrosis.
Zulueta A; Peli V; Dei Cas M; Colombo M; Paroni R; Falleni M; Baisi A; Bollati V; Chiaramonte R; Del Favero E; Ghidoni R; Caretti A
Int J Biochem Cell Biol; 2019 Nov; 116():105622. PubMed ID: 31563560
[TBL] [Abstract][Full Text] [Related]
11. Association of cystic fibrosis with abnormalities in fatty acid metabolism.
Freedman SD; Blanco PG; Zaman MM; Shea JC; Ollero M; Hopper IK; Weed DA; Gelrud A; Regan MM; Laposata M; Alvarez JG; O'Sullivan BP
N Engl J Med; 2004 Feb; 350(6):560-9. PubMed ID: 14762183
[TBL] [Abstract][Full Text] [Related]
12. Abnormal n-6 fatty acid metabolism in cystic fibrosis contributes to pulmonary symptoms.
Wheelock CE; Strandvik B
Prostaglandins Leukot Essent Fatty Acids; 2020 Sep; 160():102156. PubMed ID: 32750662
[TBL] [Abstract][Full Text] [Related]
13. Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside.
Garić D; De Sanctis JB; Wojewodka G; Houle D; Cupri S; Abu-Arish A; Hanrahan JW; Hajduch M; Matouk E; Radzioch D
J Mol Med (Berl); 2017 Oct; 95(10):1053-1064. PubMed ID: 28695226
[TBL] [Abstract][Full Text] [Related]
14. No indications for altered essential fatty acid metabolism in two murine models for cystic fibrosis.
Werner A; Bongers ME; Bijvelds MJ; de Jonge HR; Verkade HJ
J Lipid Res; 2004 Dec; 45(12):2277-86. PubMed ID: 15466369
[TBL] [Abstract][Full Text] [Related]
15. Ceramide in Pseudomonas aeruginosa infections and cystic fibrosis.
Becker KA; Grassmé H; Zhang Y; Gulbins E
Cell Physiol Biochem; 2010; 26(1):57-66. PubMed ID: 20502005
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the inflammasome by ceramide in cystic fibrosis lungs.
Grassmé H; Carpinteiro A; Edwards MJ; Gulbins E; Becker KA
Cell Physiol Biochem; 2014; 34(1):45-55. PubMed ID: 24977480
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis.
Gardner AI; Haq IJ; Simpson AJ; Becker KA; Gallagher J; Saint-Criq V; Verdon B; Mavin E; Trigg A; Gray MA; Koulman A; McDonnell MJ; Fisher AJ; Kramer EL; Clancy JP; Ward C; Schuchman EH; Gulbins E; Brodlie M
Am J Respir Crit Care Med; 2020 Oct; 202(8):1133-1145. PubMed ID: 32569477
[No Abstract] [Full Text] [Related]
18. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis.
Guilbault C; De Sanctis JB; Wojewodka G; Saeed Z; Lachance C; Skinner TA; Vilela RM; Kubow S; Lands LC; Hajduch M; Matouk E; Radzioch D
Am J Respir Cell Mol Biol; 2008 Jan; 38(1):47-56. PubMed ID: 17656682
[TBL] [Abstract][Full Text] [Related]
19. Sphingolipids: major regulators of lipid metabolism.
Worgall TS
Curr Opin Clin Nutr Metab Care; 2007 Mar; 10(2):149-55. PubMed ID: 17285002
[TBL] [Abstract][Full Text] [Related]
20. The deltaF508 mutation in the cystic fibrosis transmembrane conductance regulator alters control of essential fatty acid utilization in epithelial cells.
Bhura-Bandali FN; Suh M; Man SF; Clandinin MT
J Nutr; 2000 Dec; 130(12):2870-5. PubMed ID: 11110839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
